.png){kind=icon}
返回
Deep vein thrombosis
.png){kind=icon}
PRE
AI
DOI：10.1016/S0140-6736(05)71880-8.png)
.png){kind=icon}
.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
Deep vein thrombosis and its sequelae pulmonary embolism and post-thrombotic syndrome are some of the most common disorders. A thrombus either arises spontaneously or is caused by clinical conditions including surgery, trauma, or prolonged bed rest. In these instances, prophylaxis with low-dose anticoagulation is effective. Diagnosis of deep vein thrombosis relies on imaging techniques such as ultrasonography or venography. Only about 25% of symptomatic patients have a thrombus. Thus, clinical risk assessment and D-dimer measurement are used to rule out deep vein thrombosis. Thrombus progression and embolisation can be prevented by low-molecular-weight heparin followed by vitamin K antagonists. Use of these antagonists for 3-6 months is sufficient for many patients. Those with antithrombin deficiency, the lupus anticoagulant, homozygous or combined defects, or with previous deep vein thrombosis can benefit from indefinite anticoagulation. In cancer patients, low-molecular-weight heparin is more effective than and is at least as safe as vitamin K antagonists. Women seem to have a lower thrombosis risk than men, but pregnancy or use of oral contraceptives or hormone replacement therapy represent important risk factors.
Keyword:
MOLECULAR-WEIGHT HEPARIN
RECURRENT VENOUS THROMBOEMBOLISM
ORAL ANTICOAGULANT-THERAPY
FACTOR-V-LEIDEN
INTENSITY WARFARIN THERAPY
PROTEIN-C DEFICIENCY
COAGULATION-FACTOR-V
TERM CLINICAL-COURSE
PULMONARY-EMBOLISM
D-DIMER
AI总结
对已上传原文的论文进行重点信息的提取，主要内容包括：简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。
期刊
IF:
88.5
论文数:
5.4W
被引数:
34.8W
机构
暂无机构信息
引用论文
Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.
OAAI
OAAI分享收藏分享收藏Demonstration of a widely distributed atrial pacemaker complex in the human heart..png)
Circulation
OAAI
CirculationIF0
OAAI分享收藏分享收藏
查看更多内容